Non-opioid pain drug development is finally turning a corner. With Vertex’s recent approval paving the way, the field is entering a new era–one defined by safer, more effective treatments for neuropathic, musculoskeletal, chemotherapy-induced, and other chronic pain conditions.
From NaV 1.8-targeting molecules to novel pain pathways, biopharma’s focus is shifting toward mechanisms that redefine efficacy and tolerability. The next 12 months will be pivotal as late-stage innovators and discovery pioneers alike push forward the next wave of non-opioid breakthroughs.
This eBook explores how leaders in the space are translating preclinical promise into clinical success , and what it takes to navigate the evolving regulatory and translational landscape of pain therapeutics.
Inside, you’ll discover:
- How Vertex’s landmark approval is reshaping the non-opioid pipeline
- Next-generation NaV 1.8 and alternative target strategies from Latigo, Algiax, and others
- Case studies from Tonix, Nocion, and Axonis on advancing new mechanisms into the clinic
- Key insights from 70+ discovery, translational, and clinical experts driving non-opioid innovation
Access your free copy to explore how the Non-Opioid Pain Therapeutics Summit is accelerating the industry’s next big leap in pain management.
About Hanson Wade Group: Non-Opioid Pain Therapeutics Summit
Transforming Efficacy & Tolerability of Pain Management with Nav 1.8 & Other Targets for Neuropathic, Chemotherapy-Induced, Musculoskeletal & Other Types of Pain
For more than two decades, biopharma has struggled to develop safe and effective non-opioid pain therapies. With Vertex’s recent approval marking a long-awaited breakthrough, the momentum has reached a critical point for bringing non-opioid pain therapeutics to market.
Whether advancing NaV-targeting drugs or pursuing novel pain mechanisms, non-opioid therapeutics are now in the clinical spotlight and the next 12 months promise to be transformative.
The Non-Opioid Pain Therapeutics Summit provides a dedicated platform to harness that momentum. Attendees will be learning from companies with approvals such as Tonix, exploring late-stage strategies from innovators like Latigo and Algiax, and uncovering discovery breakthroughs from Nocion and Axonis. Join 70+ discovery, preclinical, translational, and clinical industry-based experts driving the future of non-opioid pain therapies across diverse pain indications.
Download the Event Guide
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices, and treatments.